News | News By Subject | News by Disease News By Date | Search News

Hemophilia News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
How Biogen (BIIB) Spinoff Bioverativ (BIVVV) and Its Hemophilia Med Could Make This Biotech Bleed     3/23/2017
Roche (RHHBY) Reports Death in Phase III Hemophilia Study     2/27/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market     2/6/2017
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug     11/3/2016
BioMarin (BMRN)'s Gene Therapy Yields Dramatic Results in Early Stage Hemophilia Study     7/28/2016
Shire (SHPG) Could be Eyeing Biogen (BIIB)'s Hemophilia Biz     5/16/2016
Biogen (BIIB) Spinning Off Hemophilia Business to Focus On Neurological Disorders     5/4/2016
Sources Reveal Biogen (BIIB) is Exploring Sale of Hemophilia Assets     4/12/2016
Alnylam (ALNY)’s John Maraganore Provides Leadership for RNAi Development and Biotech Industry     4/4/2016
Tiny Startup Arsia Bags $100 Million+ Hemophilia Deal with Biogen (BIIB)     12/16/2015
FDA Green Lights Octapharma USA's NUWIQ for Hemophilia A     9/15/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Analysts Say Biogen Idec, Inc. (Massachusetts) (BIIB) Must Push Into Gene Therapy To Stay Competitive     9/23/2014

News from Around the Web

Press Releases
Octapharma USA Research Results Presented At HTRS Symposium Targeting Major Challenges Facing Hemophilia Patients     4/20/2017
Bioverativ (BIVVV) Release: Long-term Safety And Efficacy Extension Study Data Of ALPROLIX For Hemophilia B Published In Thrombosis And Hemostasis     3/2/2017
Anna Protopapas To Join Bioverativ (BIVVV) Board Of Directors     3/2/2017
New Data From Shire (SHPG) Aim To Help Close The Diagnosis And Treatment Gap For People With Hemophilia     2/2/2017
uniQure (QURE) Announces FDA Breakthrough Therapy Designation For AMT-060 In Hemophilia B     1/30/2017
Xenetic Biosciences Receives $3 Million Milestone Payment From Shire (SHPG) For PSA-Recombinant SHP656 In Development For Long-Acting Treatment For Hemophilia     1/6/2017
uniQure (QURE) Announces First Clinical Data From Second Dose Cohort Of AMT-060 In Ongoing Phase I/II Trial In Patients With Severe Hemophilia B     12/5/2016
Shire (SHPG) Reports On Four Decades Of Real-World Safety Experience With FEIBA [Anti-Inhibitor Coagulant Complex]     12/5/2016
Swedish Orphan Biovitrum: Elocta Approved in Kuwait For The Treatment Of Hemophilia A     11/21/2016
Sanofi Genzyme (SNY) Says 'We're In' to Alnylam (ALNY), Invests $100 Million to Late-Stage RNAi Hemophilia Trial     11/14/2016
Swedish Orphan Biovitrum: European Study Of Real-Life Hemophilia Treatment Emphasizes Need To Improve Standard Of Care     11/14/2016
Chugai Pharma's Emicizumab Showed Continued Benefits In Patients With Hemophilia A     7/28/2016
CSL Behring Presents Phase III Data For IDELVION For Hemophilia B At The World Federation of Hemophilia 2016 World Congress     7/26/2016
Shire (SHPG) Release: ADYNOVATE Phase 3 Efficacy And Safety Data In Children To Be Showcased During International Congress Of The World Federation of Hemophilia     7/26/2016
Alnylam (ALNY) Announces New Positive Interim Phase I Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational Rnai Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders     7/25/2016